Stem Cells

Regeneus surges on back of Progenza patent news

Finfeed Archived Mar 23, 2020

The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.

Can This ASX Junior Surge Through the Pain Barrier?

Next Investors Archived Mar 02, 2020

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.